Boehringer Ingelheim

BI Spiriva combo has Phase-III success

BI Spiriva combo has Phase-III success

By

The company said in a statement that the findings indicated the Spiriva-Striverdi combination treatment could help patients "return to a more independent life."

FDA kind of OKs Lilly/BI's Lantus look-alike

FDA kind of OKs Lilly/BI's Lantus look-alike

By

Sanofi's patent lawsuit triggered the tentative approval of the Lilly-BI Lantus competitor.

 Five things for pharma marketers to know: Friday, August 15

Five things for pharma marketers to know: Friday, August 15

By

UK drug-cost watchdog backs Sovaldi, Achillion touts HCV interim results, Avastin's latest cancer indication, Ebola outbreak worsens, COPD drug gets panel nod, and study links quick reviews and black-box warnings.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.